Precision Medicine in Oncology Collaboration and Licensing Deals 2016-2024


Precision Medicine in Oncology Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals |Comprehensive deal directory 2016 to 2024

Publication date
May 2024
Number of pages
Product type
Research report
Available formats
PDF document
Report edition

Precision Medicine in Oncology Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the precision medicine in oncology deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of precision medicine in oncology deals from 2016 to 2024.

The report provides a detailed understanding and analysis of how and why companies enter precision medicine in oncology deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. 

The report includes collaboration, development, research and licensing deals.

This report contains a comprehensive listing of 821 precision medicine in oncology deals announced since 2016 including financial terms where available including links to online deal records of actual precision medicine in oncology partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of precision medicine in oncology dealmaking. 

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in precision medicine in oncology dealmaking since 2016.

Chapter 3 provides an overview of the leading precision medicine in oncology deals since 2016. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in precision medicine in oncology dealmaking with a brief summary followed by a comprehensive listing of precision medicine in oncology deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of precision medicine in oncology deals signed and announced since Jan 2016, where a contract document is available in the public domain. 

Chapter 6 provides a comprehensive and detailed review of precision medicine in oncology partnering deals signed and announced since Jan 2016. The chapter is organized by specific precision medicine in oncology technology type in focus.

The report also includes numerous table and figures that illustrate the trends and activities in precision medicine in oncology deal making since 2016.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Precision Medicine in Oncology Collaboration and Licensing Deals provides the reader with the following key benefits:

•    Understand deal trends since 2016
•    Browse precision medicine in oncology collaboration and licensing deals
•    Benchmark analysis – identify market value of transactions
•    Financials terms - upfront, milestone, royalties
•    Directory of deals by company A-Z, deal type and therapy area
•    Leading deals by value
•    Most active dealmakers
•    Identify assets and deal terms for each transaction
•    Access contract documents - insights into deal structures
•    Due diligence - assess suitability of your proposed deal terms for partner companies
•    Save hundreds of hours of research time

Report scope

Precision Medicine in Oncology Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of precision medicine in oncology trends and structure of deals entered into by leading biopharma companies worldwide.

Precision Medicine in Oncology Collaboration and Licensing Deals includes:
•    Trends in precision medicine in oncology dealmaking in the biopharma industry
•    Directory of precision medicine in oncology deal records covering pharmaceutical and biotechnology
•    The leading precision medicine in oncology deals by value
•    Most active precision medicine in oncology licensing dealmakers

Precision Medicine in Oncology Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

•    What are the precise rights granted or optioned?
•    What is actually granted by the agreement to the partner company?
•    What exclusivity is granted?
•    What is the payment structure for the deal?
•    How are sales and payments audited?
•    What is the deal term?
•    How are the key terms of the agreement defined?
•    How are IPRs handled and owned?
•    Who is responsible for commercialization?
•    Who is responsible for development, supply, and manufacture?
•    How is confidentiality and publication managed?
•    How are disputes to be resolved?
•    Under what conditions can the deal be terminated?
•    What happens when there is a change of ownership?
•    What sublicensing and subcontracting provisions have been agreed?
•    Which boilerplate clauses does the company insist upon?
•    Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
•    Which jurisdiction does the company insist upon for agreement law?

Precision Medicine in Oncology Collaboration and Licensing Deals provides the reader with the following key benefits:

•    Understand deal trends since 2016
•    Browse precision medicine in oncology collaboration and licensing deals
•    Benchmark analysis – identify market value of transactions
•    Financials terms - upfront, milestone, royalties
•    Directory of deals by company A-Z, deal type and therapy area
•    Leading deals by value
•    Most active dealmakers
•    Identify assets and deal terms for each transaction
•    Access contract documents - insights into deal structures
•    Due diligence - assess suitability of your proposed deal terms for partner companies
•    Save hundreds of hours of research time

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in precision medicine in oncology dealmaking
2.1. Introduction
2.2. Precision medicine in oncology deals over the years
2.3. Most active precision medicine in oncology dealmakers
2.4. Precision medicine in oncology deals by deal type
2.5. Precision medicine in oncology deals by therapy area
2.6. Precision medicine in oncology deals by industry sector
2.7. Deal terms for precision medicine in oncology deals
2.7.1 Precision medicine in oncology deals headline values
2.7.2 Precision medicine in oncology deal upfront payments
2.7.3 Precision medicine in oncology deal milestone payments
2.7.4 Precision medicine in oncology royalty rates

Chapter 3 – Leading precision medicine in oncology deals
3.1. Introduction
3.2. Top precision medicine in oncology deals by value

Chapter 4 – Most active precision medicine in oncology dealmakers
4.1. Introduction
4.2. Most active precision medicine in oncology dealmakers
4.3. Most active precision medicine in oncology deals company profiles

Chapter 5 – Precision medicine in oncology contracts dealmaking directory
5.1. Introduction
5.2. Precision medicine in oncology contracts dealmaking directory

Chapter 6 – Precision medicine in oncology dealmaking by technology type

Deal directory

Deal directory – Precision medicine in oncology deals by company A-Z
Deal directory – Precision medicine in oncology deals by deal type
Deal directory – Precision medicine in oncology deals by therapy area

Deal type definitions

About Biopharma Research Ltd  
Current Partnering
Current Agreements
Recent report titles from Current Partnering

Table of figures

Figure 1: Precision medicine in oncology deals since 2016
Figure 2: Active precision medicine in oncology dealmaking activity – 2016 - 2024
Figure 3: Precision medicine in oncology deals by deal type since 2016
Figure 4: Precision medicine in oncology deals by therapy area since 2016
Figure 5: Precision medicine in oncology deals by industry sector since 2016
Figure 6: Precision medicine in oncology deals with a headline value
Figure 7: Precision medicine in oncology deals with an upfront value
Figure 8: Precision medicine in oncology deals with a milestone value
Figure 9: Precision medicine in oncology deals with a royalty rate value
Figure 10: Top precision medicine in oncology deals by value since 2016
Figure 11: Most active precision medicine in oncology dealmakers 2016 - 2024
Figure 12: Precision medicine in oncology deals by technology type since 2016

Pricing options

  • $3,995: single-user (encrypted file - one user/device)
  • $5,995: multi-user (encrypted file - up to 5 users/devices)
  • $9,995: company (unencrypted PDF)

Single and Multi-user license files are encrypted PDF documents. Details of how to access using Javelin3 PDF Reader will be provided at report delivery.

Company license files are not encrypted and can be accessed using a PDF Reader.

A full explanation of license type definitions can be found here.


Our guarantee


Price promise

We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.


Latest report

If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.


Serious Security

We take your data and security seriously. See our privacy policy for details of how we manage your data.


Sales Support

If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.

2cureX, 2X Oncology, 4baseCare, 4D Path, 48Hour Discovery, A*STAR Bioinformatics Institute, A*STAR Bioprocessing Technology Institute, A*STAR Genome Institute of Singapore, A*STAR Singapore Immunology Network, A2 Biotherapeutics, Abbisko Therapeutics, Abbott Laboratories, Abbvie, Abcam, AbCellera Biologics, ABL Bio, Abramson Cancer Center, Academia Sinica, Access to Comprehensive Genomic Profiling Coalition, Acerta Pharma, Acrivon Therapeutics, Adaptive Biotechnologies, ADC Therapeutics, Addario Lung Cancer Medical Institute, Adlai Nortye, Aduro BioTech, Advanced Nuclear Medicine Ingredients, Advaxis, Affigen, Agendia, Agilent Technologies, Agios Pharmaceuticals, Aignostics, AIkido Pharma, AimedBio, Akoya Biosciences, Alamar Biosciences, Alberta Health Services, Alcedis, Alchemab, All4Cure, Allarity Therapeutics, Alligator Bioscience, Alloy Therapeutics, Almac Diagnostics, Almac Group, Alphageneron Pharmaceuticals, Altor BioScience, Amazon Web Services, Ambry Genetics, American Lung Association, American Skin Association, Amgen, Amoy Diagnostics, AnchorDx, AnHeart Therapeutics, Ankyra Therapeutics, Apocell, Apollomics, ArcherDX, Arcus Biosciences, Arizona State University, AroCell, Artios Pharma, Arvinas, Aslan Pharma, Assistance Publique-Hôpitaux de Paris, Astellas Pharma, AstraZeneca, Atlas Antibodies, Atreca, AUM Biosciences, Australian Research Data Commons, Avatamed, AVEO Oncology, Avera Health, Avera Heart Hospital of South Dakota, Baheal Pharmaceutical, Bank of America, Banner Health, Baxalta, Bayer, Baylor College of Medicine, Baylor Scott and White Research Institute, BC Cancer Agency, BC Platforms, Becton Dickinson, BeiGene, Beijing Genomics Institute (BGI), Beijing Xisike Clinical Oncology Research Foundation, Berkeley Lights, Beth Israel Deaconess Medical Center, BGI, Bio-Rad Laboratories, Biocartis, Biocept, BioCheetah, Biocodices, Biodesix, Biofidelity, Biogenar, Biognosys, BioLizard, Biomarker Collaborative, BioMarker Strategies, BioMed X Innovation Center, BioNano Genomics, Bionomics, BioNTech, BioSkryb, Biosplice, BioTheranostics, Biothera Pharmaceuticals, BioVectra, Bioyong, Bird Foundation, BitBiome, Bliss Biopharmaceutical, Blockchain Global, Blu Biotech, Bluebird Bio, Blueprint Medicines, Boehringer Ingelheim, Bonnie J. Addario Lung Cancer Foundation, Boreal Genomics, BostonGene, Bpifrance, Breath Diagnostics, Brenus Pharma, BriaCell Therapeutics, Bridge Biotherapeutics, Brigham and Women's Hospital, BrightPath Biotherapeutics, Bristol-Myers Squibb, Bristol-Myers Squibb Pakistan, Broad Institute, Brown University, Burning Rock, Busan Paik Hospital, C2i Genomics, Cadila Pharmaceuticals, California Institute for Biomedical Research, Calviri, Cambridge Cancer Genomics, Cambridge Quantum Computing, Canadian Cancer Society, CANbridge Pharmaceuticals, Cancer Genetics, Cancer Research Horizons, Cancer Research Institute, Cancer Research UK, Carina Biotech, Caring Cross, Caris Life Sciences, Carolina BioOncology Institute, CarThera, CARTI Cancer Center, Case Western Reserve University, CASI Pharmaceuticals, Catholic University Leuven, Celgene, Cellgen Diagnostics, Cellkey, Cell Medica, Cell Mogrify, Cellworks, Celsius Therapeutics, Centene, Center for Biomarker Research in Medicine, Centogene, Centre for Clinical Cancer Research, Centre for Commercialization of Regenerative Medicine (CCRM), Centre Leon Berard, Certis, CGA 369, Champions Oncology, Chao Center, Charite Universitatsmedizin Berlin, Children's Hospital Los Angeles, Children's Hospital of Orange County, Children's Medical Research Institute, Children's Minnesota, Children’s Center for Cancer and Blood Diseases (CCCBD), Christian Doppler Research Association, ChromaCode, Chugai Pharmaceutical, City of Hope, CK Life Sciences, Clearbridge Biomedics, ClearLight Diagnostics, Cleveland Clinic, Cleveland Diagnostics, Clinical Genomics, Clinical Outcomes Tracking and Analysis, CloudHealth Genomics, Clovis Oncology, Cofactor Genomics, Cogia Biotech, Color, Columbia University, Columbia University Medical Center, Complete Genomics, Compugen, ConcertAI, Concr, Congenica, Contextual Genomics, CoreBiome, COTA, Crown Bioscience, CSI Laboratories, CStone Pharmaceuticals, Culmination Bio, CureMatch, CureScience, CureVac, Curis, CvergenX, Cyclica, CYduct Diagnostics, CYTOVIA Therapeutics, Daiichi Sankyo, Dana-Farber Cancer Institute, Danish Cancer Society Research Center, Danish Center for Strategic Research into Type 2 Diabetes, Dante Labs, Dartmouth-Hitchcock Medical Center, DarwinHealth, Day One Biopharmaceuticals, Debiopharm, Decipher Biosciences, DEEP 6 AI, Deerfield Management, Definiens, Delfi Diagnostics, Dendreon, Denka, Denka-KEW Genomics, Denovo Biopharma, Department of Veterans Affairs, Desktop Genetics, Devyser Diagnostics, Diatech Pharmacogenetics, DNAmito, DNAnexus, DoMore Diagnostics, Duke University, Duke University Health System, Duke University Medical Center, DxTerity, ECOG-ACRIN Cancer Research Group, Edico Genome, Eisai, Eisai Inc, Element Biosciences, Elevation Oncology, Eli Lilly, EMD Serono, Enterome Bioscience, Epic, Epic Sciences, EpiVax Therapeutics, Epizyme, Erasmus University Medical Center, ErVimmune, Etubics, Eucure Biopharma, Euformatics, Eureka Eurostars, European Commission, European Organization for Research and Treatment of Cancer, Evaxion Biotech, Exactis Innovation, Exact Sciences, Exosome Diagnostics, Exosome Sciences, ExScientia, F1 Oncology, Fabric Genomics, Factorial Diagnostics, Falco, Fibrogen, Fight Colorectal Cancer, FivepHusion, Five Prime Therapeutics, Flagship Biosciences, Flare Therapeutics, Flatiron Health, Flow Pharma, FLX Bio, Food and Drug Administration (FDA), Fortis Therapeutics, Foundation Medicine, Fox Chase Cancer Center, Fred Hutchinson Cancer Research Center, Freenome, Friends of Cancer Research, Fudan University, Fujirebio Diagnostics, Fujitsu Laboratories, Fulgent Genetics, Fusion Pharmaceuticals, G1 Therapeutics, G42 Healthcare, Gabriella Miller Kids First Data Resource Center, Gateway for Cancer Research, GC Genome, GC Pharma, Geisel School of Medicine at Dartmouth, GeneCentric Therapeutics, Genentech, General Inception, Geneseeq, Genetic Technologies, Genetron Health, Genialis, Genome Canada, Genome Diagnostics, GenomeDx, Genome Insight, Genomic Health, Genomics England, Genomic Testing Cooperative, Genomic Vision, Genomoncology, Genoptix, Genprex, GenScript Biotech, Georgetown Lombardi Comprehensive Cancer Center, Georgetown University, Georgetown University Hospital, German Federal Ministry of Education and Research, Gibson Oncology, GI Innovation, Gilead Sciences, Global Cancer Technology, Gnosis Bioresearch, GNS Healthcare, Google, Government of Canada, Grail, Greenlight Biosciences, Gritstone Bio, GSK, Guardant Health, H3 Biomedicine, Hackensack University Medical Center, HalioDx, Harvard Medical School, HAYA Therapeutics, Healthcare Global Enterprises, Heat Biologics, Hebrew University of Jerusalem, Helen F Graham Cancer Center, Heligenics, Helomics, Henan Cancer Hospital, Hengenix Biotech, Hengrui Therapeutics, Henlius Biotech, Henry M. Jackson Foundation, HiberCell, Hoag Memorial Hospital Presbyterian, Horizon Discovery, Horizon Europe, Horizon Healthcare Services, HotSpot Therapeutics, HTG Molecular Diagnostics, HudsonAlpha Institute for Biotechnology, Hummingbird Bioscience, Huntsman Cancer Institute, IBM, IBM Watson Health, Icahn School of Medicine at Mount Sinai, IDEAYA Biosciences, Idengene, Ignyta, Ikena Oncology, Illumina, Image Analysis, ImaginAb, Imanis Life Sciences, IMBdx, Immodulon Therapeutics, Immunai, Immune Design, ImmunID Technologies, Immunovia, IMPACT Therapeutics, Imperial Innovations, Imugene, IncellDx, Incyte, Indiana University, Indica Labs, Indivumed, Inivata, InnoBation, Innoplexus, Innosuisse, Innovate UK, Innovative Genomics Initiative (IGI), Inovio Pharmaceuticals, Inserm, InSphero, Institut Curie, Institute of Cancer Research, Institut Gustave Roussy, Instituto Valenciano De Oncologia, Integrated Biobank of Luxembourg, Integrated DNA Technologies, Intellia Therapeutics, Intelliseq, Intermountain Precision Genomics, International Centers for Precision Oncology Foundation, International Myeloma Foundation, Intezyne, Invectys, Invitae, InVivoScribe, IO Biotech, Ionis Pharmaceuticals, ION Solutions, iPrime Therapeutics, iProgen Biotech, IRX Therapeutics, ITM Isotopen Technologien, Ix Therapeutics, Jackson Laboratory, Janssen Biotech, Janssen Pharmaceuticals, Janssen Pharmaceutica NV, Janssen Research & Development, Jazz Pharmaceuticals, Jefferson Healthcare, Jenga Biosciences, Jiangsu Hengrui Medicine, Johns Hopkins University, Johnson & Johnson Innovation, John Wayne Cancer Institute, Jounce Therapeutics, JSR Life Sciences, Jubilant Therapeutics, Juno Therapeutics, Juventas Therapeutics, JW Biotechnology, K2bio, Kailos Genetics, Kairos Therapeutics, Kanazawa University, Kartos Therapeutics, Karyopharm Therapeutics, Keck Graduate Institute of Applied Life Sciences, Keio Gijuku University, KEW, Kineta, Kiromic Biopharma, Kiyatec, Knight Cancer Institute, Kronos Bio, Kura Oncology, Kymab, Laboratory Corporation of America, La Jolla Institute for Allergy & Immunology, Lantern Pharma, Lantheus Holding, Latvian Institute of Organic Synthesis, Leap Therapeutics, Lee Moffitt Cancer Center, Lehigh Valley Health Network, Leica Biosystems, Leona M and Harry B Helmsley Charitable Trust, Les Laboratoires Servier, Leukemia & Lymphoma Society, Lexent Bio, LifeOmic, Life Raft Group, Li Ka Shing Foundation, Liquid Biotech USA, Loxo Oncology, Lucid Diagnostics, Lung Cancer Research Foundation, Lunit, Maccabi Healthcare Services, Macrogen, Mainz Biomed, MapKure, Massachusetts General Hospital, Massachusetts Institute of Technology, Massive Bio, Mater Research, Mayo Clinic, MD Anderson Cancer Center, med fusion, MEDIAN Technologies, Medical College of Georgia, Medical College of Wisconsin, Medical Research Council, Medical University of Bialystok, Medical University of Graz, Medical University of Vienna, MEDiC Life Sciences, Medivation, Medivizor, MedStar Health Research Institute (MHRI), Memorial Sloan Kettering Cancer Center, Mendel Health, Mercachem, Merck and Co, Merck KGaA, Merrimack Pharmaceuticals, Merus, Metabolon, Metis Therapeutics, MGI Tech, Michelson Center, Microba Life Sciences, Micronoma, Microsoft, Mie University, Mirada Medical, Mirati Therapeutics, MiRXES, Mission Bio, Mitra Biotech, Moderna, Molecular Health, Mologen, MorphoSys, Morphotek, Mount Sinai Medical Center, Mount Sinai Services, MP Group, mProbe Laboratories, MRM Proteomics, Multimmune, Multiple Myeloma Research Foundation, Munich Leukemia Laboratory, myNEO, My Personal Therapeutics, Myriad Genetics, N-of-One, NanoMab Technology, Nanostics Precision Health, NanoString Technologies, NanoView Biosciences, NantHealth, NantKwest, NantWorks, Natera, National Cancer Center, National Cancer Center of Japan, National Cancer Center of South Korea, National Cancer Centre Singapore, National Cancer Institute, National Center for Tumor Diseases, National Comprehensive Cancer Network (NCCN), National Foundation for Cancer Research, National Health Service, National Institute for Health Research (NIHR), National Institute of Molecular Genetics, National Institutes of Health, Naval Medical Research Center, Navican, Navidea Biopharmaceuticals, Navigo Proteins, NEC, Nektar Therapeutics, Neogap Therapeutics, Neogenomics, Neon Therapeutics, Nerviano Medical Sciences, Netherlands Cancer Institute, NetraMark, New Horizon Health, NewStem, New York University School of Medicine, Next Generation Manufacturing Canada, Nico, Nilogen Oncosystems, Nippon Kayaku, Nonacus, Normunity, Northern RNA, Northwestern University, Notable Labs, Novartis, NovellusDx, Novigenix, Novogene, Nucleai, Nucleix, NuProbe, Nurosene, NYU Grossman School of Medicine for Preclinical and Clinical Research, Odimma Therapeutics, Ohio State University, Olink Proteomics, Omico, OmniaBio, Oncoceutics, Oncodesign, OncoDNA, OncoGenesis, Oncoheroes Biosciences, OncoHost, OncoImmunity, Oncologie, Oncology Research Information Exchange Network, Oncology Venture, OncoMed Pharmaceuticals, Oncompass Medicine, Onconova Therapeutics, Oncora Medical, OncoSec Medical, Oncoshot, OncXerna Therapeutics, OneOncology, OneThree Biotech, ONK Therapeutics, Ono Pharmaceutical, Ontario Institute for Cancer Research, OpenBench, Optellum, OracleBio, Oregon Health Sciences University, OrigiMed, OSE Immunotherapeutics, Oswaldo Cruz Foundation (Fiocruz), Ovation, Owkin, Owlstone Medical, Oxford Nanopore Technologies, Ozette Technologies, Pacific Biosciences, Pacific Northwest Research Institute, Paige, Palantir, Pancreatic Cancer Action Network, Pancreatic Cancer Collective, Pangea Biomed, Paradigm, Parexel, PathAI, PathGroup, Paul Scherrer Institute, PAVmed, Pepscan, Personal Genome Diagnostics, Personalis, Perthera, Pfizer, Pharmatest Services, Pharus Diagnostics, Phase Genomics, Philips, Physiomics, Pierian, PierianDx, Pierre Fabre, Pillar Biosciences, Pionyr Immunotherapeutics, Plus Therapeutics, PreciseDx, Precision Biologics, Precision BioSciences, Precision for Medicine, Precision Health Informatics, Precision NanoSystems, Precision Therapeutics, Predicine, Predictive Oncology, Prelude Therapeutics, Premier Inc, PreMIT, Prenetics, Prescient Medical, PRIMA BioMed, Princess Margaret Hospital, PrognomIQ, Prognos, Promega, ProPath, Proscia, Prostate Cancer Clinical Trials Consortium, Prostate Cancer Foundation (PCF), Protagen, ProteoMediX, Puma Biotechnology, QED Therapeutics, Qiagen, Quanterix, Quantum Leap Health Care Collaborative, Quest Diagnostics, R-Pharm, Race Oncology, Radius Health, RayBiotech, Realm IDx, Redx Pharma, RefleXion Medical, Relay Therapeutics, Renato Dulbecco Foundation, Renji Hospital, Repare Therapeutics, Repertoire Genesis, Research Institute of the Hospital Universitari Vall d'Hebron, Resolution Bioscience, Reveal Biosciences, Reveal Genomics, Revolution Medicines, RiboMed, RIKEN Research Institute, Robert H. Lurie Comprehensive Cancer Center, Roche, Roche Molecular Systems, Rosetta Genomics, Royal Philips Electronics, RPRD Diagnostics, Rush University Medical Center, Rutgers Cancer Institute of New Jersey, Saga University, Salk Institute, Sanford Burnham Institute, Sanofi, Sarah Cannon Research Institute, Scailyte, Scandion Oncology, Schrodinger, Scorpion Therapeutics, Secarna Pharmaceuticals, Sema4, Seneca Therapeutics, Sengenics, SEngine Precision Medicine, Sentieon, Sentinel Diagnostics, Seoul National University, Seracare Life Sciences, Seres Therapeutics, Seven Bridges Genomics, Sheba Medical Center, Shenzhen Chipscreen Biosciences, Shepherd Therapeutics, Shimadzu, Shuttle Pharmaceuticals, Shuwen Biotech, Siemens Healthineers, Silicon Biosystems, SimBioSys, Simsen Diagnostics, Singlera Genomics, Singular Genomics Systems, Sirona Dx, SkylineDX, Skysong Innovations, SOLTI, SomaLogic, Sonic Healthcare, SOPHiA Genetics, Soricimed Biopharma, Sorrento Therapeutics, Spanish National Cancer Research Centre, Spectrum Pharmaceuticals, Spectrum Solutions, Sphingotec, St. Jude Children's Research Hospital, Stanford University, Stanford University School of Medicine, Stella Diagnostics, Step Pharma, St Jude Crosson Cancer Institute, Strata Oncology, STRATIFYER Molecular Pathology, Sun Pharma Advanced Research Company, SunTerra Biotechnology, Surefire Medical, Surrey Cancer Research Institute, Susan G. Komen for the Cure, Sutro Biopharma, Swift Biosciences, Swiss Institute of Bioinformatics (SIB), Syapse, Sydys Corporation, Syncromune, Syros Pharmaceuticals, Sysmex, Sysmex Inostics, T-Cure Bioscience, Tabula Rasa HealthCare, Taconic Biosciences, TaiRx, Takeda Pharmaceutical, Tampa General Hospital Cancer Institute, Tampere University Hospital, Tango Therapeutics, Tasly Pharmaceuticals, Tavros Therapeutics, Telix Pharmaceuticals, Telo Therapeutics, Tempus, Tennessee Oncology, TeraRecon, Tesis Biosciences, TGen Drug Development, The New York Stem Cell Foundation, The Parker Institute For Cancer Immunotherapy, Theralink Technologies, Thermo Fisher Scientific, The Technical University Of Munich, The University of Chicago Medicine, Thomas Jefferson University, Threshold Pharmaceuticals, TME Research, Tocagen, TOMA Biosciences, Tor Vergata University Hospital, TP Therapeutics, Traaser, Transcenta, Transgene, Transgenomic, Translational Drug Development, Translational Genomics Research Institute, Transmed Systems, TrovaGene, TScan Therapeutics, TumorGenesis, Turnstone Biologics, Twinstrand Therapeutics, Twist Bioscience, uBiome, UbiQ, Ultima Genomics, Ultivue, Umoja Biopharma, Univeristy of Durham, University Ann & Robert H. Lurie Children’s Hospital, University College London, University Health Network, University Hospital of Leuven, University Hospitals Case Medical Center, University of Alabama at Birmingham, University of Arizona, University of Arkansas, University of Bern, University of Bonn, University of California, University of California, Davis, University of California, San Diego, University of California Los Angeles, University of California San Francisco, University of Chicago, University of Cincinnati, University of Colorado, University of Colorado Denver, University of Greifswald, University of Heidelberg, University of Lausanne, University of Leeds, University of Maryland, University of Massachusetts, University of Melbourne, University of Miami, University of Michigan, University of Minnesota, University of Newcastle, University of New South Wales, University of North Carolina, University of Pennsylvania, University of Pittsburgh, University of Rostock, University of Surrey, University of Texas, University of Tokyo, University of Toronto, University of Utah, University of Virginia, University of Washington, University of Wisconsin, University of Wisconsin Carbone Cancer Center (UWCCC), USC Norris Comprehensive Cancer Center, US Oncology, Vaccinex, Valence Discovery, Vall d’Hebron Research Institute, Vanderbilt University, Varian Medical Systems, Ventana Medical Systems, Veracyte, Veraxa Biotech, Verily, VieCure, Viewpoint Molecular Targeting, ViewRay, Viome, Vividion Therapeutics, Viviphi, Vivo Biosciences, VolitionRX, Voltron Therapeutics, Voronoi, Vyriad, Washington University in St Louis, Waters Corporation, Weihai Weigao Medical Devices, Weill Cornell Medical College, Wellcome Trust Sanger Institute, Wellmarker Bio, WuXi NextCODE Genomics, Xcell Biosciences, xCures, Xencor, XtalPi, Yale Cancer Center, Yale School of Medicine, Yale University, Yissum Research Development, Ymir Genomics, ZAI Laboratory, ZERO Childhood Cancer, Zymeworks

Current Partnering reports provide insight into the trends and terms of partnering deals in the global life sciences sector.

Current Partnering reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.

Current Partnering analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.

Current Partnering reports source deal data from our proprietary deals and alliances database, Current Agreements. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal. In addition, deal records are updated with new data as it becomes available.

The data in the Current Agreements deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.

Current Partnering provides comprehensive coverage of the following partnering or deal types:
• Asset purchase
• Assignment
• Co-development
• Co-market
• Co-promotion
• Collaborative R&D
• Contract service
• Cross-licensing
• Development
• Distribution
• Equity purchase
• Evaluation
• Grant
• Joint venture
• Licensing
• Loan
• Manufacturing
• Marketing
• Option
• Promotion
• Research
• Royalty financing
• Settlement
• Spin out
• Sub license
• Supply
• Termination
• Warrant

Every deal record is fully categorized and includes the following data, where available:
• Industry sector
• Therapy areas
• Technology type
• Deal components
• Financial terms
• Stage of development
• Exclusivity
• Asset type
• Geographic focus
• Excluded geography
• Company press release
• SEC filing data including contract document

All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.

Financial data and contract documents displayed in deal records is obtained from public sources, where disclosed by the parties to the deal.